NASDAQ:CLVS - Clovis Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.88 +0.08 (+0.38 %)
(As of 04/19/2019 02:52 PM ET)
Previous Close$20.80
Today's Range$19.80 - $21.00
52-Week Range$11.50 - $54.20
Volume1.23 million shs
Average Volume1.83 million shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$95.39 million
Book Value$2.78 per share

Profitability

Net Income$-368,010,000.00
Net Margins-385.80%

Miscellaneous

EmployeesN/A
Market Cap$1.11 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Tuesday, February, 26th. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.68) by $0.20. The biopharmaceutical company had revenue of $30.40 million for the quarter, compared to analyst estimates of $30.46 million. Clovis Oncology had a negative return on equity of 147.39% and a negative net margin of 385.80%. The company's revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.04) earnings per share. View Clovis Oncology's Earnings History.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Clovis Oncology.

What price target have analysts set for CLVS?

11 brokers have issued 12-month price objectives for Clovis Oncology's shares. Their predictions range from $21.00 to $86.00. On average, they anticipate Clovis Oncology's stock price to reach $42.75 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price. View Analyst Price Targets for Clovis Oncology.

What is the consensus analysts' recommendation for Clovis Oncology?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:
  • 1. According to Zacks Investment Research, "Sales of the company’s sole marketed drug Rubraca recovered in the fourth quarter of 2018 on the back of awareness programs. However, the drug faced challenges in its adoption, which may continue going forward. Moreover, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Meanwhile, several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Successful development is likely to bolster the prospect of the drug. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. Clovis’ shares have underperformed the industry in the past six months. Clovis’ shares have outperformed the industry so far this year. Loss estimates have been stable ahead of the company’s Q1 earnings release. The company has a dismal record of earnings surprises in the recent quarters." (4/16/2019)
  • 2. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)

Has Clovis Oncology been receiving favorable news coverage?

Press coverage about CLVS stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Clovis Oncology earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Are investors shorting Clovis Oncology?

Clovis Oncology saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 9,480,940 shares, a decline of 11.4% from the February 28th total of 10,702,247 shares. Based on an average daily trading volume, of 1,841,211 shares, the days-to-cover ratio is presently 5.1 days. Currently, 19.0% of the shares of the company are sold short. View Clovis Oncology's Current Options Chain.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Puma Biotechnology (PBYI), Alibaba Group (BABA), Celgene (CELG), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Twitter (TWTR), General Electric (GE) and Exelixis (EXEL).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Congress Park Capital LLC (0.02%), Virtu Financial LLC (0.02%) and Conservest Capital Advisors Inc. (0.02%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Conservest Capital Advisors Inc. and Congress Park Capital LLC. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, James C Blair and Lindsey Rolfe. View Insider Buying and Selling for Clovis Oncology.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $20.88.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $1.11 billion and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is http://www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  472 (Vote Outperform)
Underperform Votes:  457 (Vote Underperform)
Total Votes:  929
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel